Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240152 | 0.83 | AKR1B1 (0.59) | AKR1B1HSPA5CYP2D6TSHRHIF1A | |
| SCHEMBL30451705 | 0.82 | AKR1B1 (0.74) | AKR1B1HSPA5CYP2D6TSHRHIF1A | |
| SCHEMBL1737314 | 0.82 | AKR1B1 (0.74) | AKR1B1HSPA5CYP2D6TSHRHIF1A | |
| SCHEMBL28482190 | 0.80 | CTBP2 (0.47) | IDO1 | |
| SCHEMBL8518720 | 0.79 | AKR1B1 (0.48) | AKR1B1HSPA5CYP2D6TSHRHIF1A | |
| 2-Allylphenol SCHEMBL9280929 | 0.79 | AKR1B1 (0.53) | AKR1B1HSPA5 | |
| SCHEMBL668441 | 0.77 | AKR1B1 (0.61) | AKR1B1HSPA5CYP2D6TSHRHIF1A | |
| SCHEMBL4006576 | 0.76 | AKR1B1 (0.65) | AKR1B1HSPA5CYP2D6TSHRHIF1A | |
| 2-Allylphenol SCHEMBL6262349 | 0.76 | GABRA1 (0.48) | AKR1B1HSPA5CYP2D6TSHRHIF1A | |
| SCHEMBL9033186 | 0.75 | AKR1B1 (0.44) | AKR1B1HSPA5CYP2D6TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673969-B2 | REACTING MIXTURE OF ALKYL-SALICYL-ALDEHYDES OR ALKYL-SALICYL-KETONES WITH HYDROXYLAMINE SULFATE OR HYDROXYLAMINE HYDROCHLORIDE; FOR EXTRACTING GALLIUM FROM WASTE EFFLUENTS FROM ORE PROCESSING, SUCH AS BAYER LIQUOR | COMSELHO NACIONAL DE DESENVOLVIMENTO CIENTIFICO E TECNOLOGICO CNPQ (BR) | 2004-01-06 | — | — | US | claimed |
| US-20020123650-A1 | Process for preparation of oximes and resulting products | CETEM - CENTRO DE TECNOLOGIA MINERAL (BR) | 2002-09-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123650-A1 | Process for preparation of oximes and resulting products | ACHE, LPO, GALE | AKR1B1 1891/4885HSPA5 3591/4885CYP2D6 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.